Silence Therapeutics settles patent dispute with Alnylam
11-12-2018
eccolo / iStockphoto.com
Biotech company Silence Therapeutics has filed a case on supplementary protection certificates (SPCs) at the English Patents Court against Alnylam and The Medicines Company.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Silence Therapeutics, UK High Court, SPCs, Alnylam, The Medicines Company, patents
